WAYNE, Pa., March 21, 2018 /PRNewswire/ -- Egalet Corporation
(Nasdaq: EGLT) ("Egalet"), a fully integrated specialty
pharmaceutical company focused on developing, manufacturing and
commercializing innovative treatments for pain and other
conditions, today announced that members of the Egalet clinical and
development teams will be presenting at two upcoming conferences.
The presentations are as follows:
- Karsten Lindhardt, Ph.D.,
Egalet's chief scientific officer, will present "The Guardian™
Technology - Injection Molding of Tablets" tomorrow, March 22, at the SMi 15th Annual Controlled
Release Delivery Conference in London,
England. Dr. Lindhardt will present on the second day of the
two-day conference during the key note address at 11:40 local
time.
- Colville Brown, M.D.,
Egalet medical director, will present at the Insight Exchange
Network Conference titled, "Responding to the Opioid Crisis:
Litigation, Regulation, & Reform" in Philadelphia, PA on April 16 and 17, 2018. Dr. Brown will present
"How is Pharma Responding to the Opioid Crisis? Regulation and
Alternative Updates" on April 16 at
3:00 p.m. EDT.
For more information about the SMi conference,
visit
https://www.smi-online.co.uk/pharmaceuticals/uk/controlled-release
and for the Insight Exchange Network conference, please visit
https://www.insightxnetwork.com/responding-to-the-opioid-crisis.html.
About Egalet
Egalet, a fully integrated specialty pharmaceutical company, is
focused on developing, manufacturing and commercializing innovative
treatments for pain and other conditions. Egalet has three approved
products: ARYMO® ER (morphine sulfate) extended-release
tablets for oral use —CII, developed using Egalet's proprietary
Guardian™ Technology, OXAYDO® (oxycodone HCI, USP)
tablets for oral use only —CII and SPRIX® (ketorolac
tromethamine) Nasal Spray. Using Guardian Technology, Egalet has
developed a pipeline of clinical-stage, product candidates for
which we are seeking partners including Egalet-002, an
abuse-deterrent, extended-release, oral oxycodone formulation for
the management of pain severe enough to require daily,
around-the-clock, long-term opioid treatment and for which
alternative treatment options are inadequate. Guardian Technology
can be applied broadly across different classes of pharmaceutical
products and can be used to develop combination products that
include multiple active pharmaceutical ingredients with similar or
different release profiles.
For full prescribing information on ARYMO ER, including
the boxed warning and medication guide, please visit arymoer.com.
For full prescribing information on SPRIX, including the boxed
warning and medication guide, please visit sprix.com. For full
prescribing information on OXAYDO, including the boxed warning and
medication guide, please visit oxaydo.com.
Safe Harbor
Statements included in this press release (including but not
limited to upcoming milestones) that are not historical in nature
and contain the words "anticipate," "believe," "estimate,"
"expect," "intend," "may," "plan," "predict," "project," "suggest,"
"target," "potential," "will," "would," "could," "should,"
"continue," "look forward to" and other similar expressions are
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are based on management's current expectations and are
subject to known and unknown uncertainties and risks. Actual
results could differ materially from those discussed due to a
number of factors, including, but not limited to: Egalet's ability
to continue as a going concern; Egalet's ability to remain listed
on the Nasdaq; the potential impact of strengthening the ARYMO ER
label; the success of Egalet's clinical trials, including the
timely recruitment of trial subjects and meeting the timelines
therefor; Egalet's ability to obtain and maintain regulatory
approval of Egalet's products and product candidates and the
labeling claims that Egalet believes are necessary or desirable for
successful commercialization of its products and product
candidates; the impact of strengthening any of the labels for
Egalet's products; Egalet's ability to maintain the intellectual
property position of Egalet's products and product candidates;
Egalet's ability to identify and reliance upon qualified third
parties to manufacture its products; Egalet's ability to
commercialize its products, and to do so successfully; the costs of
commercialization activities, including marketing, sales and
distribution; the size and growth potential of the markets for
Egalet's products and product candidates, and Egalet's ability to
service those markets; Egalet's ability to obtain reimbursement and
third-party payor contracts for its products; Egalet's ability to
service its debt obligations; Egalet's ability to raise additional
funds to execute its business plan and growth strategy on terms
acceptable to Egalet, if at all; Egalet's ability to find and hire
qualified sales professionals; the rate and degree of receptivity
in the marketplace and among physicians to Egalet's products; the
success of products that compete with Egalet's that are or become
available; the regulatory environment and social concerns about
limiting the use of opioids; general market conditions; and other
risk factors set forth in Egalet's Annual Report on Form 10-K and
Quarterly Reports on Form 10-Q filed with the United States
Securities and Exchange Commission (SEC) and in other filings
Egalet makes with the SEC from time to time. While Egalet may elect
to update these forward-looking statements at some point in the
future, it specifically disclaims any obligation to update or
revise any forward-looking-statements contained in this press
release whether as a result of new information or future events,
except as may be required by law.
Media and Investor Contact:
E. Blair Clark-Schoeb
Senior Vice President, Communications
Email: ir@egalet.com
Tel: 484-259-7370
View original content with
multimedia:http://www.prnewswire.com/news-releases/egalet-to-present-at-upcoming-conferences-300617141.html
SOURCE Egalet Corporation